University of Bamberg

EQS-News: Mathias Daehn joins Cherry SE as CFO and member of the Executive Board

Retrieved on: 
Saturday, April 15, 2023
CFO, MAN, Partnership, Supervisory board, IPO, University, University of Bamberg, Cherry, Management

Munich, April 3, 2023 – Cherry SE [ISIN: DE000A3CRRN9] announced today that Dr. Mathias Daehn (55) has been appointed Chief Financial Officer by the Supervisory Board effective April 15, 2023.

Key Points: 
  • Munich, April 3, 2023 – Cherry SE [ISIN: DE000A3CRRN9] announced today that Dr. Mathias Daehn (55) has been appointed Chief Financial Officer by the Supervisory Board effective April 15, 2023.
  • Bernd Wagner, who has been CFO at Cherry SE and its various predecessor companies since 2017, has left the company by mutual agreement effective March 31, 2023.
  • Mathias Daehn has served as CFO in a range of listed businesses and has extensive experience in the capital markets and supporting company growth.
  • Marcel Stolk, Chairman of the Board of Directors of Cherry SE: "We are delighted to welcome Mathias Daehn as CFO at an important time for Cherry SE.

Cardior Appoints Axel-Sven Malkomes as Chief Financial Officer

Retrieved on: 
Thursday, November 3, 2022
Pharmaceutical, Health, Clinical Trials, Cardiology, Doctor of Philosophy, CFO, RNA, Technology, University of Bamberg, Kellogg School of Management, INSEAD, Therapy, Growth, Compliance, Heart, Merck, Deutsche Bank, Information technology, Industry, Degenerative disease, Barclays, Merck Group, Lehman Brothers, Knowledge, Northwestern University, Patient, University, Dresdner Bank, University of Science and Technology, CEO, Credit Suisse, Entrepreneurship, Medicine, Medication, Risk, CBO, RNA transfection, Donaldson, Lufkin & Jenrette, 3i, MD, Pharmaceutical industry, Management, MediGene

Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO).

Key Points: 
  • Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO).
  • Mr. Malkomes brings to Cardior nearly 30 years of life science industry experience from executive roles, investment banking, healthcare investing, and corporate development positions.
  • His decades of experience in the industry, with a strong track record across the financial side of biotech, will be an important addition to our team.
  • Mr. Malkomes started his career in investment banking at a range of banking institutions, namely Dresdner Bank, Sal.

DGAP-News: Stabilus S.A.: Stefan Bauerreis to become the Group's new Chief Financial Officer, succeeding Mark Wilhelms in June 2022

Retrieved on: 
Monday, December 20, 2021
Schaeffler Group, Business administration, University of Bamberg, Supervisory board, Industry, Group, Financial Oversight and Management Board for Puerto Rico, Goal, CFO, University, Corporate Accountability, Head, Management, Medical device

Stabilus S.A.: Stefan Bauerreis to become the Group's new Chief Financial Officer, succeeding Mark Wilhelms in June 2022

Key Points: 
  • Stabilus S.A.: Stefan Bauerreis to become the Group's new Chief Financial Officer, succeeding Mark Wilhelms in June 2022
    The issuer is solely responsible for the content of this announcement.
  • Stabilus S.A.: Stefan Bauerreis to become the Group's new Chief Financial Officer, succeeding Mark Wilhelms in June 2022
    - Stefan Bauerreis appointed as Chief Financial Officer effective June 1, 2022
    - CFO Mark Wilhelms will not extend his contract and is therefore resigning as of September 30, 2022
    Luxembourg/Koblenz, December 20, 2021 - The Supervisory Board of Stabilus, one of the world's leading suppliers of gas springs, damping solutions and electromechanical drives for motion control, has appointed Stefan Bauerreis (48) as Chief Financial Officer effective June 1, 2022.
  • Stefan Bauerreis has many years of experience in the automotive supplier sector and in industry.
  • Stefan Bauerreis, said: "Stabilus is an innovative and fast-growing listed company that enjoys an excellent reputation in the market.

Isarna Therapeutics Appoints Claus Schalper as CEO

Retrieved on: 
Thursday, September 30, 2021
Health, Other Science, Research, Science, Pharmaceutical, Optical, Biotechnology, Biochemistry, Retina, Siberian State Medical University, Therapy, Clinical trial, Neoplasm, Anticalin, RNA transfection, XL, RNA, Novartis, Uveitis, Business administration, Feinberg School of Medicine, Bayer, TGF, Cancer, Arthur Andersen, AMD, Patient, Berlin, Board of directors, University of Bamberg, MD, Diabetic retinopathy, Warwick Business School, RTÉ Executive Board, Biology, NASH, CEO, University, CMO, Master of Business Administration, FEBO, Ophthalmology, Leadership, Gold, Medical school, MBA, Research, Drug development, DME, Safety, Fibrosis, Macular edema, Doctor of Philosophy, Eye, Vienna General Hospital, Management, Pharmaceutical industry

Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer.

Key Points: 
  • Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer.
  • Mr. Schalper joins Isarna with over 20 years of experience as an executive and serial entrepreneur in the life science and biotech industries.
  • Isarna has reached an exciting stage of development for its lead program, ISTH0036, which has broad applicability in a range of ophthalmology indications, said Claus Schalper, CEO of Isarna Therapeutics.
  • Mr. Schalper began his career with Arthur Andersen and subsequently served as CEO for several companies in the technology industry.